Rüdiger Horst Robert Ridder
Geen lopende functies
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Peter Pack | M | 58 |
mtm laboratories AG
mtm laboratories AG Medical SpecialtiesHealth Technology mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results. mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer. | 9 jaar |
Robert J. Silverman | M | 64 |
mtm laboratories AG
mtm laboratories AG Medical SpecialtiesHealth Technology mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results. mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer. | - |
Magnus von Knebel Döberitz | M | - |
mtm laboratories AG
mtm laboratories AG Medical SpecialtiesHealth Technology mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results. mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer. | 14 jaar |
Gerald Heinz Möller | M | 80 |
mtm laboratories AG
mtm laboratories AG Medical SpecialtiesHealth Technology mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results. mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer. | - |
Erich Maximilian Platzer | M | 74 |
mtm laboratories AG
mtm laboratories AG Medical SpecialtiesHealth Technology mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results. mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer. | - |
Berthold Hackl | M | - |
mtm laboratories AG
mtm laboratories AG Medical SpecialtiesHealth Technology mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results. mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer. | - |
Werner Schäfer | M | 76 |
mtm laboratories AG
mtm laboratories AG Medical SpecialtiesHealth Technology mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results. mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer. | 8 jaar |
Arthur Franken | M | - |
mtm laboratories AG
mtm laboratories AG Medical SpecialtiesHealth Technology mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results. mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer. | - |
Doeberitz Christina von Knebel | F | - |
mtm laboratories AG
mtm laboratories AG Medical SpecialtiesHealth Technology mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results. mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer. | - |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Duitsland | 9 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Rüdiger Horst Robert Ridder
- Persoonlijk netwerk